Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder

Psychiatry Research

Volumn 208, Issue 3, 2013, Pages 285-287

  Hopkins, Seth C ^a   Reasner, David S ^a   Koblan, Kenneth S ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

COMT; Major depressive disorder; Venlafaxine

Indexed keywords

CATECHOL METHYLTRANSFERASE; PLACEBO; VENLAFAXINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MODIFIER GENE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION;

COMT; MAJOR DEPRESSIVE DISORDER; VENLAFAXINE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CATECHOL O-METHYLTRANSFERASE; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; METHIONINE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; VALINE; YOUNG ADULT;

EID: 84880702621     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.04.021     Document Type: Article

References (14)

1. Axelrod J., Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. The Journal of Biological Chemistry 1958, 233:702-705.
2. Carboni E., Tanda G.L., Frau R., Di C.G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. Journal of Neurochemistry 1990, 55:1067-1070.
3. Collins F.S. Research agenda. Opportunities for research and NIH. Science 2010, 327:36-37.
4. Epstein R.S., Frueh F.W., Geren D., Hummer D., McKibbin S., O'Connor S., Randhawa G., Zelman B. Payer perspectives on pharmacogenomics testing and drug development. Pharmacogenomics 2009, 10:149-151.
5. Garriock H.A., Kraft J.B., Shyn S.I., Peters E.J., Yokoyama J.S., Jenkins G.D., Reinalda M.S., Slager S.L., McGrath P.J., Hamilton S.P. A genomewide association study of citalopram response in major depressive disorder. Biological Psychiatry 2010, 67:133-138.
6. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:9991-9996.
7. Kocabas N.A. Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD). CNS & Neurological Disorders-Drug Targets 2012, 11:264-272.
8. Leuchter A.F., Cook I.A., Hunter A.M., Korb A.S. A new paradigm for the prediction of antidepressant treatment response. Dialogues in Clinical Neuroscience 2009, 11:435-446.
9. Licinio J., Wong M.L. Pharmacogenomics of antidepressant treatment effects. Dialogues in Clinical Neuroscience 2011, 13:63-71.
10. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melen K., Julkunen I., Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995, 34:4202-4210.
11. Malhotra A.K., Murphy G.M., Kennedy J.L. Pharmacogenetics of psychotropic drug response. American Journal of Psychiatry 2004, 161:780-796.
12. Moron J.A., Brockington A., Wise R.A., Rocha B.A., Hope B.T. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. Journal of Neuroscience 2002, 22:389-395.
13. Perlis R.H., Fijal B., Adams D.H., Sutton V.K., Trivedi M.H., Houston J.P. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biological Psychiatry 2009, 65:785-791.
14. Takano A., Halldin C., Farde L. SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study. Psychopharmacology (Berl) 2013, 226(1):147-153.